Physician profile
Tova E Winters
NPI 1184139826
$1,229.24
in general payments reported to CMS, 2019-2025
23 companies · $88.01 in 2025
The $88.01 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $195 · 2022: $475 · 2023: $227 · 2024: $244 · 2025: $88.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $269.13 | 2022-2025 | |
| Lilly USA, LLC | $144.35 | 2021-2024 | Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $107.67 | 2022-2024 | Airsupra, Breztri |
| Pfizer INC. | $104.28 | 2021-2024 | |
| Amgen INC. | $76.34 | 2022-2023 | Evenity, Prolia |
| Novo Nordisk INC | $71.52 | 2021-2022 | |
| Exact Sciences Corporation | $57.20 | 2023-2024 | Cologuard Collection Kit |
| Irhythm Technologies, INC. | $50.17 | 2022-2023 | Zio Xt Patch |
| Bayer Healthcare Pharmaceuticals INC. | $39.72 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $32.99 | 2022 | |
| Merck Sharp & Dohme LLC | $31.96 | 2022-2024 | Gardasil 9, Gardasil, Capvaxive |
| Novartis Pharmaceuticals Corporation | $27.82 | 2022 | |
| Lundbeck LLC | $24.23 | 2024 | Rexulti |
| Amneal Pharmaceuticals LLC | $23.75 | 2024 | Unithroid |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.18 | 2023 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21.02 | 2021 | |
| Azurity Pharmaceuticals, INC. | $20.58 | 2024 | Edarbi |
| Kyowa Kirin, INC. | $19.75 | 2024 | Crysvita |
| Daiichi Sankyo INC. | $19.46 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.12 | 2021 | |
| Abbott Laboratories | $17.91 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.31 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tova Winters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.